Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation

British Journal of Haematology

Volumn 126, Issue 5, 2004, Pages 697-703

  Sanchez, Joaquin ^a   Casaño, Javier ^a   Alvarez, Miguel A ^a   Roman Gomez, Jose ^a   Martin, Carmen ^a   Martinez, Francisco ^a   Gomez, Pedro ^a   Serrano, Josefina ^a   Herrera, Concepcion ^a   Torres, Antonio ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Allogeneic transplantation; OX40 lymphocytes; Regulatory T cells

Indexed keywords

BUSULFAN; CD134 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR; MELPHALAN; THYMOCYTE ANTIBODY; TNFRSF4 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; APLASTIC ANEMIA; ARTICLE; CHILD; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; LYMPHOBLASTOMA; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; T LYMPHOCYTE; ACUTE DISEASE; ADOLESCENT; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; HISTOCOMPATIBILITY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PRESCHOOL CHILD; PROSPECTIVE STUDY; REGRESSION ANALYSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 4544268251     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05108.x     Document Type: Article

References (29)

1. Antin, J. (2002) Long-term care after hematopoietic-cell transplantation in adults. New England Journal of Medicine, 347, 36-42.
2. Atkinson, K., Horowitz, M.M., Gale, R.P., Lee, M.B., Rimm, A.A. & Bortin, M.M. (1989) Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplantation, 4, 247-254.
3. +CD25high regulatory cells in human peripheral blood. Journal of Immunology, 167, 1245-1253.
4. +high regulatory T cell function. Journal of Immunology, 169, 6210-6217.
5. high regulatory T-cells. Blood, 103, 2410-2416.
6. + immunoregulatory T cells: new therapeutics for graft-versus-host disease. Journal of Experimental Medicine, 196, 401-406.
7. + T cells with regulatory properties from human blood. Journal of Experimental Medicine, 193, 1303-1310.
8. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nature Medicine, 9, 1144-1150.
9. + cells: a naturally occurring population of regulatory T cells. Blood, 98, 2736-2744.
10. Gadisseur, A.P.A., Gratama, J.W., Lamers, C., van Esser, J.W.J., Bolhuis, R.L.H. & Cornelissen, J.J. (1999) Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation. Bone Marrow Transplantation, 23, 1013-1017.
11. + lymphocytes in the marrow graft. Bone Marrow Transplantation, 23, 443-450.
12. high regulatory T cells. Blood, 104, 895-903.
13. + cells with regulatory properties isolated from peripheral blood. Journal of Experimental Medicine, 193, 1285-1294.
14. +) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation. Blood, 98, 3162-3164.
15. Lamb, L.S. Jr, Abhyankar, S.A., Hazlett, L., O'Neal, W., Folk, R.S., Vogt, S., Parrish, R.S., Bridges, K., Henslee-Downey, P.J. & Gee, A.P. (1999) Expression of CD134 (OX-40) on T-cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease. Cytometry, 380, 238-243.
16. Przepiorka, D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J. & Thomas, ED. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplantation, 15, 825-828.
17. Ratanatharathorn, V., Ayash, L., Lazarus, H.M., Fu, J. & Uberti, J.P. (2001) Chronic graft-versus-host disease: clinical manifestation and therapy. Bone Marrow Transplantation, 28, 121-129.
18. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155, 1151-1164.
19. Serrano, J., Roman, J., Sanchez, J., Jimenez, A., Castillejo, J.A., Herrera, C., Gonzalez, M.G., Reina, L., Rodriguez, M.C., Alvarez, M.A., Maldonado, J. & Torres, A. (2000) Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood, 95, 2659-2665.
20. + suppressor T cells. Journal of Experimental Medicine, 193, F41-F45.
21. + T cells is associated with an increased risk of graft-versus-host disease following HLA-identical stem cell transplantation in humans. Blood, 103, 1140-1146.
22. Takeda, I., Ine, S., Killeen, N., Ndhlovu, L.C., Murata, K., Satomi, S., Sugamura, K & Ishii, N. (2004) Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. Journal of Immunology, 172, 3580-3589.
23. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. Journal of Experimental Medicine, 193, 1311-1317.
24. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood, 99, 3493-3499.
25. Teshima, T. & Ferrara, J.L.M. (2002) Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Seminars in Hematology, 39, 15-22.
26. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. Journal of Experimental Medicine, 188, 287-296.
27. Tittle, T., Weinberg, A.D., Steinkeler, C.A. & Maziarz, R.T. (1997) Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood, 89, 4652-4658.
28. Vogelsang, G.B. (2001) How I treat chronic graft-versus-host disease. Blood, 97, 1196-1201.
29. Vogelsang, G.B., Lee, L. & Bensen-Kennedy, D.M. (2003) Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annual Review of Medicine, 54, 29-52.